To implement a coordinated program of research into use of antiretroviral (ARV) therapy and the reduction of risk behavior in resource constrained (Thailand) and resource limited (Cambodia) settings. The primary theme of this program is the appropriate and cost-effective use of ARV therapy in developing countries.
Specific Aims 1. To assess strategies for inexpensive and logistically simple monitoring of ARV therapy 2. To compare strategies of immediate versus delayed treatment of HIV-infected children in resource limited settings 3. To assess the optimal timing for initiation of ARV therapy in the management of HIV/TB co-infection 4. To investigate behavioral interventions for the reduction of risk behavior and HIV transmission in patients treated with ARV therapy 5. To link the projects using a family unit recruitment strategy 6. To strengthen clinical and prevention research capacity in Thailand and Cambodia 7. To guide clinical and public health policy in Thailand and Cambodia Methods The proposed CIPRA program will investigate treatment and behavioral interventions that will inform public health policy in Thailand, Cambodia and other countries of the region. The research methodologies to be used are randomized clinical trials and observational cohorts. The individual projects involve multiple recruitment sites in Thailand and Cambodia. In the course of conducting this research, training will be provided to strengthen the capacity of Thai and Cambodian investigators and health professionals in the conduct of clinical and public health research. The projects will be linked by a family recruitment strategy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI053741-05
Application #
7478685
Study Section
Special Emphasis Panel (ZAI1-EC-A (S4))
Program Officer
Bupp, Jane E
Project Start
2004-09-30
Project End
2009-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
5
Fiscal Year
2008
Total Cost
$998,662
Indirect Cost
Name
HIV-Nat, the Thai Red Cross AIDS Rch Center
Department
Type
DUNS #
671556129
City
Bangkok
State
Country
Thailand
Zip Code
10330
Paul, Robert; Apornpong, Tanakorn; Prasitsuebsai, Wasana et al. (2018) Cognition, Emotional Health, and Immunological Markers in Children With Long-Term Nonprogressive HIV. J Acquir Immune Defic Syndr 77:417-426
Paul, Robert; Prasitsuebsai, Wasana; Jahanshad, Neda et al. (2018) Structural Neuroimaging and Neuropsychologic Signatures in Children With Vertically Acquired HIV. Pediatr Infect Dis J 37:662-668
Bunupuradah, Torsak; Hansudewechakul, Rawiwan; Kosalaraksa, Pope et al. (2015) HLA-DRB1454 and predictors of new-onset asthma in HIV-infected Thai children. Clin Immunol 157:26-9
Ananworanich, Jintanat; Kerr, Stephen J; Jaimulwong, Tanyathip et al. (2015) Soluble CD163 and monocyte populations in response to antiretroviral therapy and in relationship with neuropsychological testing among HIV-infected children. J Virus Erad 1:196-202
Kerr, Stephen J; Puthanakit, Thanyawee; Vibol, Ung et al. (2014) Neurodevelopmental outcomes in HIV-exposed-uninfected children versus those not exposed to HIV. AIDS Care 26:1327-35
Intasan, Jintana; Bunupuradah, Torsak; Vonthanak, Saphonn et al. (2014) Comparison of adherence monitoring tools and correlation to virologic failure in a pediatric HIV clinical trial. AIDS Patient Care STDS 28:296-302
Puthanakit, Thanyawee; Ananworanich, Jintanat; Vonthanak, Saphonn et al. (2013) Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study. Pediatr Infect Dis J 32:501-8
Bunupuradah, Torsak; Kosalaraksa, Pope; Vibol, Ung et al. (2013) Impact of antiretroviral therapy on quality of life in HIV-infected Southeast Asian children in the PREDICT study. AIDS Patient Care STDS 27:596-603
Puthanakit, Thanyawee; Saphonn, Vonthanak; Ananworanich, Jintanat et al. (2012) Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis 12:933-41
Haas, David W; Mootsikapun, Piroon; Ruxrungtham, Kiat et al. (2012) Clinical perspectives on human genetic screening to prevent nevirapine toxicity. Per Med 9:773-782

Showing the most recent 10 out of 16 publications